GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Price-to-Funds-From-Operations

CHRO (Channel Therapeutics) Price-to-Funds-From-Operations : (As of Dec. 13, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Channel Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.